A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
- Study Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia
- Teva Identifier
- TV48125-PN-20028
- ClinicalTrials.gov Identifier
- NCT03965091
- Study Status
- Terminated
- Trial Condition(s)
- Fibromyalgia
- Interventions
- Drug: Fremanezumab|Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 75 Years
- Trial Duration
- July 31, 2019 - January 19, 2022
- Phase
- Phase 2